BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 31973813)

  • 1. PTUPB ameliorates high-fat diet-induced non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in mice.
    Sun CC; Zhang CY; Duan JX; Guan XX; Yang HH; Jiang HL; Hammock BD; Hwang SH; Zhou Y; Guan CX; Liu SK; Zhang J
    Biochem Biophys Res Commun; 2020 Mar; 523(4):1020-1026. PubMed ID: 31973813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COX-2/sEH Dual Inhibitor Alleviates Hepatocyte Senescence in NAFLD Mice by Restoring Autophagy through Sirt1/PI3K/AKT/mTOR.
    Zhang CY; Tan XH; Yang HH; Jin L; Hong JR; Zhou Y; Huang XT
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A COX-2/sEH dual inhibitor PTUPB alleviates lipopolysaccharide-induced acute lung injury in mice by inhibiting NLRP3 inflammasome activation.
    Yang HH; Duan JX; Liu SK; Xiong JB; Guan XX; Zhong WJ; Sun CC; Zhang CY; Luo XQ; Zhang YF; Chen P; Hammock BD; Hwang SH; Jiang JX; Zhou Y; Guan CX
    Theranostics; 2020; 10(11):4749-4761. PubMed ID: 32308747
    [No Abstract]   [Full Text] [Related]  

  • 4. A COX-2/sEH dual inhibitor PTUPB ameliorates cecal ligation and puncture-induced sepsis in mice via anti-inflammation and anti-oxidative stress.
    Zhang YF; Sun CC; Duan JX; Yang HH; Zhang CY; Xiong JB; Zhong WJ; Zu C; Guan XX; Jiang HL; Hammock BD; Hwang SH; Zhou Y; Guan CX
    Biomed Pharmacother; 2020 Jun; 126():109907. PubMed ID: 32114358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apigenin ameliorates HFD-induced NAFLD through regulation of the XO/NLRP3 pathways.
    Lv Y; Gao X; Luo Y; Fan W; Shen T; Ding C; Yao M; Song S; Yan L
    J Nutr Biochem; 2019 Sep; 71():110-121. PubMed ID: 31325892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet.
    Zhu W; Feng PP; He K; Li SW; Gong JP
    Biochem Biophys Res Commun; 2018 Oct; 505(2):523-529. PubMed ID: 30269815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asperuloside alleviates lipid accumulation and inflammation in HFD-induced NAFLD via AMPK signaling pathway and NLRP3 inflammasome.
    Shen Q; Chen Y; Shi J; Pei C; Chen S; Huang S; Li W; Shi X; Liang J; Hou S
    Eur J Pharmacol; 2023 Mar; 942():175504. PubMed ID: 36641101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deletion of Thioredoxin-interacting protein ameliorates high fat diet-induced non-alcoholic steatohepatitis through modulation of Toll-like receptor 2-NLRP3-inflammasome axis: Histological and immunohistochemical study.
    Mohamed IN; Sarhan NR; Eladl MA; El-Remessy AB; El-Sherbiny M
    Acta Histochem; 2018 Apr; 120(3):242-254. PubMed ID: 29482933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development.
    He K; Zhu X; Liu Y; Miao C; Wang T; Li P; Zhao L; Chen Y; Gong J; Cai C; Li J; Li S; Ruan XZ; Gong J
    Oncotarget; 2017 Jun; 8(23):37657-37672. PubMed ID: 28499273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dietary saturated fatty acid and polyunsaturated fatty acid oppositely affect hepatic NOD-like receptor protein 3 inflammasome through regulating nuclear factor-kappa B activation.
    Sui YH; Luo WJ; Xu QY; Hua J
    World J Gastroenterol; 2016 Feb; 22(8):2533-44. PubMed ID: 26937141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet.
    Yang G; Lee HE; Lee JY
    Sci Rep; 2016 Apr; 6():24399. PubMed ID: 27075683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deletion of Perilipin 5 Protects Against Hepatic Injury in Nonalcoholic Fatty Liver Disease via Missing Inflammasome Activation.
    Asimakopoulou A; Engel KM; Gassler N; Bracht T; Sitek B; Buhl EM; Kalampoka S; Pinoé-Schmidt M; van Helden J; Schiller J; Weiskirchen R
    Cells; 2020 May; 9(6):. PubMed ID: 32481590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cathepsin B inhibition ameliorates the non-alcoholic steatohepatitis through suppressing caspase-1 activation.
    Tang Y; Cao G; Min X; Wang T; Sun S; Du X; Zhang W
    J Physiol Biochem; 2018 Nov; 74(4):503-510. PubMed ID: 30019185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exercise suppresses NLRP3 inflammasome activation in mice with diet-induced NASH: a plausible role of adropin.
    Yang W; Liu L; Wei Y; Fang C; Liu S; Zhou F; Li Y; Zhao G; Guo Z; Luo Y; Li L
    Lab Invest; 2021 Mar; 101(3):369-380. PubMed ID: 33268842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage.
    Huang S; Wu Y; Zhao Z; Wu B; Sun K; Wang H; Qin L; Bai F; Leng Y; Tang W
    Metabolism; 2021 Jul; 120():154797. PubMed ID: 33984334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiolipin inhibitor ameliorates the non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation.
    Liu J; Wang T; He K; Xu M; Gong JP
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):8158-8167. PubMed ID: 31599445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy.
    Yu X; Hao M; Liu Y; Ma X; Lin W; Xu Q; Zhou H; Shao N; Kuang H
    Eur J Pharmacol; 2019 Dec; 864():172715. PubMed ID: 31593687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deficiency of the Purinergic Receptor 2X
    Blasetti Fantauzzi C; Menini S; Iacobini C; Rossi C; Santini E; Solini A; Pugliese G
    Oxid Med Cell Longev; 2017; 2017():8962458. PubMed ID: 29270247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mangiferin Ameliorates HFD-Induced NAFLD through Regulation of the AMPK and NLRP3 Inflammasome Signal Pathways.
    Yong Z; Ruiqi W; Hongji Y; Ning M; Chenzuo J; Yu Z; Zhixuan X; Qiang L; Qibing L; Weiying L; Xiaopo Z
    J Immunol Res; 2021; 2021():4084566. PubMed ID: 34734090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA adenosine deaminase (ADAR1) alleviates high-fat diet-induced nonalcoholic fatty liver disease by inhibiting NLRP3 inflammasome.
    Xiang R; Liu Y; Fan L; Jiang B; Wang F
    Lab Invest; 2022 Oct; 102(10):1088-1100. PubMed ID: 35690649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.